Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

Publisher: La Merie Publishing
Pages: 56
Format: PDF and Online
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0126
Release Date: May of 2016

250.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting epithelial growth factor receptor (EGF-R) in comparison with originator anti-EGF-R antibodies to treat solid tumors as of May 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of solid tumors. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

Table of Contents

1.         Sales of Anti-EGF-R Antibodies

2.         Originator Anti-EGF-R Antibodies
Erbitux Approved Indications & Pipeline
Vectibix Approved Indications & Pipeline
Nimotuzumab Approved Indications & Pipeline
Portrazza Approved Indications & Pipeline

3.         Biosuperior Anti-EGF-R Antibodies
3rd Generation Anti-EGF-R Antibodies
Bispecific Anti-EGF-R Antibodies
Anti-EGF-R Antibody Drug Conjugates

4.         Biosimilar Anti-EGF-R Antibodies
Erbitux Biosimilar Antibodies:
-           Developments in Regulated Markets
-           Developments in Less Regulated Markets

5.         Corporate Anti-EGF-R Biosimilar & Biosuperior Antibody Pipelines



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top